Zhifei Biotech announced that the freeze-dried human rabies vaccine independently developed by its subsidiary Zhifeilong Koma has applied for production registration and obtained a “Notice of Acceptance” issued by the State Drug Administration. If this project progresses smoothly, it will further enrich the company's virus vaccine varieties, improve the company's product layout, and strengthen the company's competitive advantage in the market.

Zhifei Biotech announced that the freeze-dried human rabies vaccine independently developed by its subsidiary Zhifeilong Koma has applied for production registration and obtained a “Notice of Acceptance” issued by the State Drug Administration. If this project progresses smoothly, it will further enrich the company's virus vaccine varieties, improve the company's product layout, and strengthen the company's competitive advantage in the market.